Inxight Drugs

U.S. Department of Health & Human Services Divider Arrow

National Institutes of Health Divider Arrow

NCATS

This repository is under review for potential modification in compliance with Administration directives.

Return Home Inxight Drugs

Home
Browse Drugs
Search
- Structure Search
- Sequence Search
Downloads
About

Show Filters

Hide Filters

Development Status

US Previously Marketed

6

All Match

Any Match

Exclude Selected

Exclude Selected

Primary Target

Human immunodeficiency virus type 1 protease

6

Leishmania amazonensis

4

UDP-glucuronosyltransferase 1-1

4

Human immunodeficiency virus type 2 pol protein

2

Protease

2

All Match

Any Match

Exclude Selected

Exclude Selected

Highest Phase

Approved

6

All Match

Any Match

Exclude Selected

Exclude Selected

Approval Year

1995

2

1996

4

All Match

Any Match

Exclude Selected

Exclude Selected

Condition

HIV infection

6

All Match

Any Match

Exclude Selected

Exclude Selected

Treatment Modality

Primary

6

All Match

Any Match

Exclude Selected

Exclude Selected

CNS Activity

CNS Penetrant

6

All Match

Any Match

Exclude Selected

Exclude Selected

Originator

Merck

4

Roche

2

All Match

Any Match

Exclude Selected

Exclude Selected

Substance Class

Chemical

6

All Match

Any Match

Exclude Selected

Exclude Selected

Code System

FDA UNII

6

PUBCHEM

6

CAS

5

DAILYMED

5

DRUG BANK

5

All Match

Any Match

Exclude Selected

Exclude Selected

ATC Level 1

ANTIINFECTIVES FOR SYSTEMIC USE

3

All Match

Any Match

Exclude Selected

Exclude Selected

ATC Level 2

ANTIVIRALS FOR SYSTEMIC USE

3

All Match

Any Match

Exclude Selected

Exclude Selected

ATC Level 3

DIRECT ACTING ANTIVIRALS

3

All Match

Any Match

Exclude Selected

Exclude Selected

ATC Level 4

Protease inhibitors

3

All Match

Any Match

Exclude Selected

Exclude Selected

Substance Form

Salts, Hydrates, Esters, etc.

4

Principal Form

2

All Match

Any Match

Exclude Selected

Exclude Selected

Showing 1 - 6 of 6 results

First page disabled
Previous page disabled
1
Next page disabled
Next page disabled

INDINAVIR ANHYDROUS

9MG78X43ZT

Export Data
Search for Structure

Status:

US Previously Marketed

First approved in 1996

Class (Stereo):

CHEMICAL (ABSOLUTE)

Targets:

UDP-glucuronosyltransferase 1-1

Human immunodeficiency virus type 1 protease

Leishmania amazonensis

Conditions:

Indinavir is an antiretroviral drug for the treatment of HIV infection. Indinavir is a protease inhibitor with activity against Human Immunodeficiency Virus Type 1 (HIV-1). Protease inhibitors block the part of HIV called protease. HIV-1 protease is ...

an enzyme required for the proteolytic cleavage of the viral polyprotein precursors into the individual functional proteins found in infectious HIV-1. Indinavir binds to the protease active site and inhibits the activity of the enzyme. This inhibition prevents cleavage of the viral polyproteins resulting in the formation of immature non-infectious viral particles. Protease inhibitors are almost always used in combination with at least two other anti-HIV drugs.

SAQUINAVIR

L3JE09KZ2F

Export Data
Search for Structure

Status:

US Previously Marketed

First approved in 1995

Class (Stereo):

CHEMICAL (ABSOLUTE)

Targets:

Human immunodeficiency virus type 1 protease

Human immunodeficiency virus type 2 pol protein

Conditions:

Saquinavir (brand names Invirase and Fortovase) is an antiretroviral drug used together with other medications to treat or prevent HIV/AIDS. Saquinavir is an inhibitor of HIV protease. HIV protease is an enzyme required for the proteolytic cleavage o...

f viral polyprotein precursors into individual functional proteins found in infectious HIV. Saquinavir is a peptide-like substrate analog that binds to the protease active site and inhibits the activity of the enzyme. Saquinavir inhibition prevents cleavage of the viral polyproteins resulting in the formation of immature noninfectious virus particles. The most frequent adverse events with saquinavir in either formulation are mild gastrointestinal symptoms, including diarrhea, nausea, loose stools & abdominal discomfort. Invirase is better tolerated than Fortovase.

INDINAVIR SULFATE

771H53976Q

Export Data
Search for Structure

Status:

US Previously Marketed

First approved in 1996

Class (Stereo):

CHEMICAL (ABSOLUTE)

Targets:

UDP-glucuronosyltransferase 1-1

Human immunodeficiency virus type 1 protease

Leishmania amazonensis

Conditions:

Indinavir is an antiretroviral drug for the treatment of HIV infection. Indinavir is a protease inhibitor with activity against Human Immunodeficiency Virus Type 1 (HIV-1). Protease inhibitors block the part of HIV called protease. HIV-1 protease is ...

an enzyme required for the proteolytic cleavage of the viral polyprotein precursors into the individual functional proteins found in infectious HIV-1. Indinavir binds to the protease active site and inhibits the activity of the enzyme. This inhibition prevents cleavage of the viral polyproteins resulting in the formation of immature non-infectious viral particles. Protease inhibitors are almost always used in combination with at least two other anti-HIV drugs.

INDINAVIR

5W6YA9PKKH

Export Data
Search for Structure

Status:

US Previously Marketed

First approved in 1996

Class (Stereo):

CHEMICAL (ABSOLUTE)

Targets:

UDP-glucuronosyltransferase 1-1

Human immunodeficiency virus type 1 protease

Leishmania amazonensis

Conditions:

Indinavir is an antiretroviral drug for the treatment of HIV infection. Indinavir is a protease inhibitor with activity against Human Immunodeficiency Virus Type 1 (HIV-1). Protease inhibitors block the part of HIV called protease. HIV-1 protease is ...

an enzyme required for the proteolytic cleavage of the viral polyprotein precursors into the individual functional proteins found in infectious HIV-1. Indinavir binds to the protease active site and inhibits the activity of the enzyme. This inhibition prevents cleavage of the viral polyproteins resulting in the formation of immature non-infectious viral particles. Protease inhibitors are almost always used in combination with at least two other anti-HIV drugs.

INDINAVIR SULFATE ETHANOLATE

34OB95C8AE

Export Data
Search for Structure

Status:

US Previously Marketed

First approved in 1996

Class (Stereo):

CHEMICAL (ABSOLUTE)

Targets:

UDP-glucuronosyltransferase 1-1

Human immunodeficiency virus type 1 protease

Leishmania amazonensis

Conditions:

Indinavir is an antiretroviral drug for the treatment of HIV infection. Indinavir is a protease inhibitor with activity against Human Immunodeficiency Virus Type 1 (HIV-1). Protease inhibitors block the part of HIV called protease. HIV-1 protease is ...

an enzyme required for the proteolytic cleavage of the viral polyprotein precursors into the individual functional proteins found in infectious HIV-1. Indinavir binds to the protease active site and inhibits the activity of the enzyme. This inhibition prevents cleavage of the viral polyproteins resulting in the formation of immature non-infectious viral particles. Protease inhibitors are almost always used in combination with at least two other anti-HIV drugs.

SAQUINAVIR MESYLATE

UHB9Z3841A

Export Data
Search for Structure

Status:

US Previously Marketed

First approved in 1995

Class (Stereo):

CHEMICAL (ABSOLUTE)

Targets:

Human immunodeficiency virus type 1 protease

Human immunodeficiency virus type 2 pol protein

Conditions:

Saquinavir (brand names Invirase and Fortovase) is an antiretroviral drug used together with other medications to treat or prevent HIV/AIDS. Saquinavir is an inhibitor of HIV protease. HIV protease is an enzyme required for the proteolytic cleavage o...

f viral polyprotein precursors into individual functional proteins found in infectious HIV. Saquinavir is a peptide-like substrate analog that binds to the protease active site and inhibits the activity of the enzyme. Saquinavir inhibition prevents cleavage of the viral polyproteins resulting in the formation of immature noninfectious virus particles. The most frequent adverse events with saquinavir in either formulation are mild gastrointestinal symptoms, including diarrhea, nausea, loose stools & abdominal discomfort. Invirase is better tolerated than Fortovase.

HHS VULNERABILITY DISCLOSURE

For language access assistance, contact the NCATS Public Information Officer

National Center for Advancing Translational Sciences (NCATS),
6701 Democracy Boulevard, Bethesda MD 20892-4874 • 301-594-8966


			version 1.1